Latest Info on Dry Macular Degeneration (AMD)

Latest Info on Dry Macular Generation as of 10/29/26

 

There’s still no cure, but a few updates…

 

A Setback for a Wet AMD Implant, Gene Therapies Move Ahead, and New Clues from AAO

 

New Trials

 

A one-time gene therapy for geographic atrophy reaches Phase 3.

Ocugen has started a Phase 3 trial of OCU410, a single-dose gene therapy aimed at geographic atrophy (the advanced form of dry AMD). The first patient was dosed in early September, and the company plans to enroll about 237 patients across the U.S., Canada, and Europe. Earlier Phase 2 results showed a 31% reduction in lesion size and no serious safety problems tied to the treatment. The FDA gave OCU410 a special fast-track-style designation (Regenerative Medicine Advanced Therapy), which could shorten the review process. Topline results are expected in the second half of 2028.

*Why it matters:* Today’s GA treatments (Syfovre and Izervay) are repeat eye injections. A one-and-done gene therapy would be a completely different proposition. Still very early days — this trial has to succeed first. *Status: Phase 3, newly recruiting. Source: company disclosures, September 2026.*

 

Kamuvudine K8 slows geographic atrophy by 54% in a small Phase 2 trial.

Presented at the American Academy of Ophthalmology (AAO) meeting this month, this one is interesting: K8 is a tiny bioerodible implant — smaller than a grain of rice — that goes into the eye through a standard office injection and slowly dissolves over three months. In a 30-patient trial, the 0.7-mg dose cut GA lesion growth by 54% over six months, with the effect looking stronger in the second three months (70%) than the first (43%). In a subgroup, treated eyes gained about 4 letters of vision compared to untreated eyes. No serious safety problems were seen, and — notably — no increase in wet AMD or inflammation, which has been a concern with some GA treatments.

*Why it matters:* Quarterly dosing, an office injection with no refrigeration needed, and no wet-AMD conversion signal are all patient-friendly features. But 30 patients is tiny; a bigger Phase 3 is needed. *Status: Phase 2 complete; Phase 3 planned. Source: Ophthalmology Times, October 2026.*

 

Treatment News

 

Wet AMD setback: EyePoint’s DURAVYU mits Phase 3 goal

DURAVYU was a sustained-release implant designed to deliver tyrosine kinase inhibitor medicine continuously in wet AMD, with the goal of drastically cutting the number of injections patients need. On October 19, EyePoint announced that its Phase 3 LUCIA trial missed its primary endpoint — the implant wasn’t shown to be statistically equivalent to standard aflibercept (Eylea) for preserving vision. There was a bright spot: patients on DURAVYU needed 38% fewer treatments. But the miss was decisive — the company’s stock lost nearly 80% of its value on the news.

*Why it matters:* This is a reminder that “fewer injections” isn’t enough on its own — the vision outcome has to match. For now, DURAVYU’s future in wet AMD is uncertain. This is wet AMD news, but it shows the high bar any new therapy must clear. *Status: Phase 3 failed primary endpoint. Source: EyePoint announcement / Seeking Alpha call transcript, October 19, 2026.*

 

Research Worth Watching

 

Do GLP-1 weight-loss drugs affect AMD risk?

A huge study — more than 300 million patient records — presented at AAO 2026 looked at GLP-1 drugs (like Ozempic and Wegovy) and AMD. At first glance, users of these drugs appeared more likely to have AMD. But after accounting for the fact that GLP-1 users are more likely to have diabetes, high blood pressure, and high cholesterol — conditions already linked to AMD — the association flipped: the drugs were actually linked to *lower* AMD odds. The researchers’ takeaway: the other health conditions are the real story here, not the medication.

*Why it matters:* Many people with AMD also take GLP-1s for diabetes or weight management, so this question comes up in clinics. The answer so far: don’t blame the drug; blame the underlying conditions it was prescribed for. More rigorous studies are needed. *Status: Observational research, presented at AAO 2026, October 9–12. Source: HealthDay/Drugs.com, October 21, 2026.*

 

A non-viral gene therapy shows early promise for GA

PulseSight’s PST-611 is an unusual one: a gene therapy delivered without a virus as the carrier, given as a single dose. In a tiny first-in-human trial (six patients with advanced dry AMD/geographic atrophy), five of six patients showed early signs of slowed retinal cell loss — between 35% and 52% on the measured biomarkers — and several patients spontaneously reported seeing better. Safety was good.

*Why it matters:* Non-viral delivery could eventually mean a simpler, safer procedure than current gene therapies that require surgery. But six patients and a post-hoc analysis is the very definition of “encouraging, not proven.” *Status: Phase 1 complete. Source: PulseSight announcement at EURETINA, October 7, 2026.*

 

Merck’s remigromig hits its mark in wet AMD

Merck presented one-year results from its BRUNELLO study of remigromig (MK-3000) at AAO 2026. It’s a new approach that works by activating the Wnt pathway rather than blocking VEGF like current drugs. Both dose groups matched ranibizumab (Lucentis) on vision improvement at one year.

*Why it matters:* Wet AMD treatment has been dominated by anti-VEGF drugs for two decades. A drug that works through a totally different pathway could eventually offer new options, especially for people who don’t respond well to current medicines. *Status: Phase IIb/III; pivotal program expected to begin in 2027. Source: DelveInsight pipeline roundup, October 2026.*

 

 

Also This Week

 

Actress Judi Dench said in a BBC Radio 4 interview that advancing macular degeneration — first diagnosed in 2012 — has now ended her stage and screen career, making reading scripts and recognizing faces impossible. She’s adapting, staying engaged through radio and public appearances. A high-profile reminder that AMD affects millions of everyday lives, and that vision loss deserves honest, public conversation rather than quiet resignation.

*Source: BBC Radio 4 Today interview, October 23, 2026.*

 

**Sources:

– EyePoint LUCIA topline results call transcript — Seeking Alpha, Oct 19, 2026: https://seekingalpha.com/article/4955265-eyepoint-inc-eypt-discusses-lucia-phase-iii-topline-results-for-duravyu-in-wet-age-related

– AAO 2026: Kamuvudine K8 slows geographic atrophy growth in Phase 2 — Ophthalmology Times, Oct 2026: https://www.ophthalmologytimes.com/view/aao-2026-kamuvudine-k8-slows-geographic-atrophy-growth-phase-2

– GLP-1 receptor agonists and AMD — HealthDay/Drugs.com, Oct 21, 2026: https://www.drugs.com/news/aao-association-between-glp-1-receptor-agonists-amd-explored-131722.html

– PulseSight PST-611 Phase I efficacy data — EURETINA presentation, Oct 7, 2026: https://trial.medpath.com/news/pulsesight-s-pst-611-shows-35-52-slowing-of-retinal-cell-loss-biomarkers-in-phase-i-geographic-atrophy-trial

– Merck remigromig BRUNELLO one-year results at AAO 2026 — reported in DelveInsight pipeline roundup, Oct 2026: https://www.openpr.com/news/4670899/diabetic-macular-edema-clinical-trial-pipeline-delveinsight

– Ocugen OCU410 Phase 3 (ArMaDa3) status — company disclosures, Sept–Oct 2026: https://tradersunion.com/news/companies/show/3892034-ocugen-phase3-ocu410/

– Judi Dench interview — BBC Radio 4 Today, Oct 23, 2026: https://particle.news/story/judi-dench-says-macular-degeneration-has-ended-her-stage-and-screen-career

 

Click Here to Learn How To Safely and Naturally Save Your Sight